natgillin/translations-raw huggingface dataset:
Said aiming means may comprise means to generate a beam of visible light, such as laser means. The means to direct the electromagnetic radiation may be adapted to position the apparatus at a preselected distance from the zone of body tissue to be irradiated. 
Uređaj u skladu s patentnim zahtjevom 10, naznačen time, da je sredstvo za usmjeravanje elektromagnetskog zračenja prilagođeno za postavljanje uređaja na unaprijed određenoj udaljenosti od područja očnog tkiva koje će se ozračiti.
A conventional subsequent working process for the manufacture of a completed surface consists in the assembling of several individual veneer sheets in an assembly factory, or "splicing factory," and in the subsequent trimming of said assembled/spliced veneer surfaces. 
Konvencionalni postupak proizvodnje završene površine, koji slijedi nakon toga, sastoji se u spajanju nekoliko pojedinačnih listova furnira u tvornici za sklapanje, ili u "tvornici za spajanje", i u obrubljivanju navedenih sklopljenih/spojenih površina furnira.
The compound of claim 10, wherein the disease or condition which can be influenced by inhibiting the enzyme 11B-hydroxysteroid dehydrogenase (HSD) 1 is a metabolic disorder. 
Spoj prema zahtjevu 10, naznačen time da je bolest ili stanje na koje se može utjecati inhibiranjem enzima 11f- hidroksisteroid dehidrogenaze (HSD) 1 metabolički poremećaj.
The method according to claim 1, wherein the clinker is ground to finenesses (according to Blaine) of 2000 to 10000 cm2/g, either with or without sulfate carriers in the form of alkaline and/or alkaline earth sulfates. 
Postupak sukladno barem jednom od zahtjeva 1 do 9, naznačen time što je ternesit klinker samljeven na finoću (prema Blaineu) veću od 10000 cm"/g, i 3 do 99%, i poželjno 5 do 50%, sadržaja faze klinker je prisutan kao X-zraka amorfne faze.
The process according to any one of claims 1 to 7, characterized in that the at least one partially or totally lithium-neutralized water-soluble organic polymer is added before and/or during and/or after step a), if the at least one mineral material is PCC and/or is added before and/or during and/or after grinding step d), if the at least one mineral material is GCC, or, if steps e) and f) are not carried out and/or is added after grinding step d) and before and/or during and/or after screening and/or concentrating step e), if step e) is performed alone and/or is added before and/or during and/or after dispersing step f), if step f) is carried out. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, karakteriziran na način da je barem jedan djelomično ili potpuno litijem neutraliziran u vodi topljiv organski polimer dodan prije i/ili nakon koraka mljevenja d) i prije i/ili za vrijeme i/ili nakon prosijavanja i/ili ukoncentriravanja u koraku e), ako je korak e) izveden samostalno i/ili je dodan prije i/ili za vrijeme i/ili nakon koraka disperzije f), ako je korak f) proveden.
The coating particles according to Claim 5, wherein a volume average primary particle size of the core particles 5 µm to 1000 µm. 
Čvrsta formulacija prema zahtjevu 1, naznačena time, da prosječni volumen primarne veličine čestice od jezgrenih čestica, iznosi od 5 um do 1000 um.
Anti-TNF-alpha monoclonal antibodies such as Infliximab, Certolizumab pegol, Golimumab, Adalimumab and AME-527 from Applied Molecular Evolution 
anti-TNF-alfa monoklonalnih antitijela kao što su infliksimab, certolizumab pegol, golimumab, adalimumab i AME-527 od tvrtke Applied Molecular Evolution;
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:111 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 110; 
(c) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 111i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 110;
Such an element could be a CD and/or a DVD or any other data-carrying element having a similar hole and shape or any other data-carrying element. 
Takav element može biti CD i/ili DVD ili bilo koji drugi element koji je nosač podataka i koji ima sličnu rupu i oblik, ili bilo koji drugi element koji je nosač podataka.
A genetically modified murine animal comprising a replacement at an endogenous murine IL-6 locus of a murine gene encoding IL-6 with a human gene encoding human IL-6, wherein the human gene encoding human IL-6 is under control of endogenous murine regulatory elements at the endogenous murine IL-6 locus. 
Genetički modificirani miš koji sadrži zamjenu na lokusu endogenog miša IL-6 mišjeg gena koji kodira IL-6 sa ljudskim genom koji kodira ljudski IL-6, naznačen time da je ljudski gen koji kodira ljudski IL-6 pod kontrolom regulacijskih elemenata endogenog miša na lokusu endogenog miša IL-6.
The extended release tablet formulation of claim 1, wherein the matrix comprises: pramipexole or a salt thereof to 5 wt-% 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 4, naznačena time, da matrica sadrži oko: (a) pramipeksol ili njegovu sol 0.05 do 5 mas. %
In another aspect, the composition is suitable for subcutaneous administration. 
pri čemu taj pripravak je vodeni sastav koji je prikladan za supkutanu primjenu.
According to the invention, the minerals are selected from the group comprising natural calcium carbonate, synthetic, precipitated calcium carbonate, kaolin, talcum, aluminium hydroxide, aluminium silicate, titanium dioxide and mixtures thereof, and preferably comprise natural and/or synthetic calcium carbonate. 
Uporaba prema zahtjevu 1, naznačena time da je vodeni pripravak disperzija ili suspenzija prirodnog kalcijevog karbonata, sintetskog, istaloženog kalcijevog karbonata, kaolina, talka, aluminijevog hidroksida, aluminijevog silikata, titanijevog dioksida ili njihovih smjesa, punila ili pigmenata.
SUMMARY The present invention overcomes this problem mainly through a new secondary cooling system being designed for a high mass flow and by providing induction heating to have the slab temperature higher by at least 100° C. 
Predstavljeni izum nadilazi ove poteškoće uglavnom pomoću novog sekundarnog sustava hlađenja koji je osmišljen za visoki maseni protok 1 koji provodi indukcijsko zagrijavanje kako bi temperatura slaba bila veća za najmanje 100%C.
reacting a glycosylated sulfamidase with an alkali metal periodate for a time period of no more than 4 h, and 
reagiranje glikolizirane sulfamidaze s perjodatoam alkalijskog metala u trajanju od najviše 4 sata, i
The coating solution is appropriately prepared by mixing deionized water to a concentrated emulsion that contains approximately 50% solids by weight of polyvinylidene chloride copolymer to adjust to the appropriate concentration. 
Otopina za oblaganje je odgovarajuće pripremljena miješanjem deionizirane vode do koncentrirane emulzije koja sadrži približno 50% čvrste faze po masi poliviniliden klorid kopolimera, da bi se podesila odgovarajuća koncentracija.
The excitation wavelength is set at 485 nM, and the emission wavelenght is 530 nM. 
Pobudna valna duljina podešena je na 485 nM, a emisijska je bila 530 nM.
When opening the packaging with an angle of 180°, the level of the back part between the two hinges is preferably higher than the level of the two sides of the inner part. 
Kada se otvori pakiranje pod kutom od 180", poželjno je da je nivo stražnjeg dijela između dva panta viši od nivoa dvije strane unutarnjeg dijela.
Apparatus according to claim 1, wherein the control group (32) comprises: at least one heat exchange unit, placed in the fluid circuit (37) and destined to enable a thermal regulation of the thermoregulation fluid, and 
– najmanje jednu jedinicu za izmjenu topline, koja se nalazi u fluidnom krugu (37) i služi za omogućavanje termoregulacije termoregulacijskog fluida, te – najmanje jednu crpku koja se nalazi u fluidnom krugu (37), koja se može nalaziti između sabirne jedinice (35) i jedinice za izmjenu topline.
"Alken" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having 2 to 15 carbon atoms in the chain. 
"Alken" znači alifatska ugljikovodična skupina s dvostrukom vezom ugljik-ugljik, a može biti nerazgranata ili razgranata, s 2 do 15 ugljikovih atoma u lancu.
The infusion phase can itself be a single administration in each cycle of say 1 to 72 hours, more usually of about 1, 3 or 24 hours; or an infusion on a daily basis in the infusion phase of the cycle for preferably 1 to 5 hours, especially 1 or 3 hours; or an infusion on a weekly basis in the infusion phase of the cycle for preferably 1 to 3 hours, especially 2 or 3 hours. 
Faza infuzije može sama po sebi biti jedna primjena u svakom ciklusu od recimo 1 do 72 sata, uobičajenije od oko 1, 3 ili 24 sata; ili infuzija na dnevnoj bazi u fazi infuzije ciklusa poželjno 1 do 5 sati, posebno 1 ili 3 sata; ili infuzija na tjednoj bazi u fazi infuzije ciklusa od poželjno 1 do 3 sata, posebno 2 ili 3 sata.
is hydrogen or C1-C6 alkyl optionally substituted with hydroxy, trifluoromethyl, or pyrrolidinyl; or R2, R3, and the nitrogen to which they are attached form piperidinyl, piperazinyl optionally substituted with C1-C6 alkyl, or morpholinyl; 
je vodik ili C1-C6 alkil, izborno supstituiran s hidroksi, trifluormetilom ili pirolidinilom; ili, R3 i dušik na kojeg su vezani tvore piperidinil, piperazinil, izborno supstituiran s C1-C6 alkilom, ili morfolinil;
A sixth process (F) according to the invention for preparing a compound of formula (I) comprises reacting a compound of formula (VII) 
= Drugi postupak (B) dobivanja spoja formule (I) sastoji se u reakciji spoja formule (VII)
one or more conjugates of a carrier protein and a capsular saccharide of a bacterium selected from the group Neisseria meningitidis type A, Neisseria meningitidis type C, Neisseria meningitidis type W and Neisseria meningitidis type Y; a Neisseria meningitidis type B (MenB) outer membrane vesicle or LOS or a conjugated MenB capsular saccharide; a Vi saccharide from Salmonella typhi conjugated to a carrier protein; or 
umrtvljenih cijelih stanica bakterije Bordetella pertussis (Pw); dvije ili više nestaničnih komponenata uzročnika hripavca (Pa); jednog ili više konjugata proteinskog nosača s kapsularnim saharidom bakterije koju se bira iz skupine koju čine Neisseria meningitidis tip A, Neisseria meningitidis tip C, Neisseria meningitidis tip W i Neisseria meningitidis tip Y; vezikule od vanjske membrane ili LOS ili konjugiranog kapsularnog saharida MenB iz bakterije Neisseria meningitidis tip B (MenB), ili njegovog derivata; saharida Vi iz bakterije Salmonella typhi konjugiranog na proteinski nosač; ili antigena virusa Hepatitisa A.
The oxycodone hydrochloride composition of claim 1 or 2, under the proviso that the 14-hydroxycodeinone level in the composition is not zero. 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 5 ppm.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-iljamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
Particularly Preferred compounds of the present invention include: 
Datum objave europske prijave patenta:
The aqueous agrochemical suspension according to claim 1, wherein the suspension is a composition and the amount of the at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin is within a range of 5 to 60 parts by weight, the amount of the inorganic thickener is within a range of 4 to 30 parts by weight and the amount of the dispersant is within a range of 5 to 85 parts by weight, as opposed to 100 parts by weight of 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole. 
Vodena agrokemijska suspenzija u skladu sa patentnim zahtjevom 1, gdje suspenzija je kompozicija i količina barem jedne vrste alkohola odabrane iz grupe koja se sastoji od etilen glikola, propilen glikola i glicerina je u okviru opsega od 5 do 60 dijelova po masi, količina neorganskog sredstva za zgušnjavanje je u okviru opsega od 4 do 30 dijelova po masi i količina dispergirajućeg sredstva je u okviru opsega od 5 do 85 dijelova po masi, za razliku od 100 dijelova po masi 2-(2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifenil]-4,5-dihidrooksazola.
Example 9 Transporter Binding Assay Measurements of [3H]-5-HT Uptake into Rat Cortical Synaptosomes 
303.1 Primjer 9 Test koji veže transporter Mjerenje [3H]-5-HT kortikalnim sinaptosomima štakora
Use of the stack of claim 6 for absorbing oil spilt on a water or coastline surface, comprising unfolding the stack and disposing the modular devices as a one-dimensional or two-dimensional interconnected flat array onto the spilt oil or onto a coastal area to be protected from the spilt oil. 
Korištenje skupa iz zahtjeva 6 za apsorpciju prolivene nafte na vodi ili priobalnoj površini, a tvori jednodimenzionalni ili dvodimenzionalni skup na području prolivene nafte ili na priobalnom području koje se štiti od prolivene nafte.
the orthomyxovirus is selected from the group consisting of human influenza virus, avian influenza virus, swine influenza virus, equine influenza virus, and feline influenza virus; 
- - ortomiksovirus, rekombinantni ortomiksovirus ili reasortirani orthomiksovirus izabran između virusa ljudske gripe, virusa ptičje gripe, virusa svinjske gripe, virusa konjske gripe, virusa mačje gripe;
After stirring at room temperature overnight, the solvent is removed in vacuo and the residue is dissolved in water (20 ml). 
Nakon miješanja preko noći pri sobnoj temperaturi, otapalo se odstrani u vakuumu i ostatak se otopi u vodi (20 ml).
Number of Mice (n) 
Broj međunarodne objave:
combining said antigen/adjuvant mixture of (a) with an oil component and an emulsifier to form an antigen/adjuvant/oil component mixture; and 
kombiniranju navedene smjese antigen/adjuvans iz (a) s uljnom komponentom i emulgatorom kako bi se dobilo smjesu antigen/adjuvans/uljna komponenta; i
The term “prodrug” as employed herein includes a precursor to a compound of formula I that, upon bioactivation, can form a bioactive metabolite of formula 1. 
Termin "prolijek", kao što se ovdje upotrebljava uključuje prekursor do spoja formule I, koji nakon bioaktivacije, može tvoriti bioaktivni metabolit formule I. Primjeri takvih prolijekova mogu se pronaći u Design of Prodrugs, urednika H.
integrating an env gene in such cells culturing the cells to obtain a cell line stably expressing gag, pol, rev and env proteins 
Vili. integraciju env gena u takvim stanicama koristeći ekspresijski vektor ix. uzgoj stanica za dobivanje stamene linije stabilno izražavajući gag, pol, rev i env proteine
A powdery composition comprising a steroidal molecule; and a pharmaceutically acceptable carrier having a specific surface area of 200-1000 m2/g; wherein the steroidal molecule is dissolved in a solvent absorbed onto the surface of the pharmaceutically acceptable carrier and wherein the steroidal molecule is present in the solvent in a supersaturated concentration. 
Praškasti kompozit, naznačen time, da sadrži steroidnu molekulu; i amorfni silicijev dioksid koji ima specifičnu površinu od najmanje 250 m2/g; gdje je steroidna molekula otopljena u otapalu apsorbiranom na površinu amorfnog silicijevog dioksida i gdje je steroidna molekula prisutna u otapalu u superzasićenoj koncentraciji.
A B2 agonist as defined in any one of claims 1 and 3 to 7, for simultaneous, concurrent, separate or sequential use in combination with an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 11 or 12, while producing less heart side-effects than a therapeutically equivalent combination of tiotropium with the B2 agonist. 
B2 agonist kako je definirano u patentnom zahtjevu 1 ili 3, naznačen time, da je namijenjen za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s antagonistom M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 ili 2 za liječenje dišnih bolesti kao što je definirano u zahtjevu 7 ili 8.
Subsequently, 313 g of donepezil hydrochloride hydrate and 840 g of low-substituted hydroxypropylcellulose were mixed with the granulate in a biconic mixer. 
Nakon toga je 313 g donepezil hidroklorid hidrata 1 840 g nisko supstituirane hidroksipropilceluloze pomiješano sa granulatom u bikoničnom mikseru.
The pharmaceutical composition of claim 1, wherein the disease associated with CFTR protein malfunction is cystic fibrosis. 
Tvar za uporabu u skladu s patentnim zahtjevom 4, pri čemu je bolest povezana s nepravilnošću funkcije CFTR proteina cistična fibroza.
The lighting module of claim 1, wherein said microchip is configured to operate the switching device such that 880 mA to 910 mA is delivered to the light emitting diode when said thermistor senses between 23° C. to 27° C. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da navedeni mikročip konfiguriran da upravlja preklopnim sklopom tako da se LED diodi isporučuje 680 mA do 910 mA kada navedeni termistor odčita temperaturu u rasponu 23?C€ - 27%C.
is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C1-4alkyl, C1-4alkyloxy, C1-4alkylsulfonyl, perfluoroC1-4alkyl, perfluoroC1-4alkyloxy, diC1-4alkylamino, hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C1-4alkyl and perfluoroC1-4alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C1-4alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C3-8cycloalkyl; or C5-7cycloalkenyl; 
je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, C1-4alkil, C1-4alkiloksi, C1-4alkilsulfonil, perfluoroC1-4alkil, perfluoroC1-4alkiloksi, diC1-4alkilamino, hidroksil, i fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, C1-4alkil i perfluoroC1-4alkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo i C1-4alkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; C3-8cikloalkil; ili C5-7cikloalkenil;
a first formulation comprising a reducing agent capable of reducing disulfide bonds in hair to produce free thiol groups, and 
(a) prvu formulaciju koja sadrži sredstvo za redukciju koje je u stanju reducirati disulfidne veze u kosi da bi se dobile slobodne tiolne skupine, i
is independently selected from: H, 
R* je neovisno odabran od:
The method of claim 8, wherein the composition is administered at a dosage range from about 105 pfu to about 109 pfu. 
Sastav za uporabu prema zahtjevu 10 ili 11, naznačen time, da se sastav primjenjuje u doznom rasponu od 10? pfu do 10? pfu.
Another aspect of the present invention is the provision of a process for the manufacture of a polymer fiber comprising the steps of melt-spinning of a polymer and subsequent treatment of the fiber with ionizing radiation. 
Postupak proizvodnje polimernog vlakna u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koracima predenja polimera iz taline, uz naknadnu obradu ionizirajućim zračenjem.
The topical veterinary composition for use according to any preceding claim wherein the parasite is an ectoparasite. 
Sastav za uporabu prema zahtjevu 11, naznačen time, da parazit je ektoparazit.
The method of claim 13, wherein the lipid component and the protein component are each preheated at a temperature in said first temperature range. 
Postupak prema zahtjevu 11, naznačen time što se lipidna komponenta i proteinska komponenta svaka prethodno zagrijavaju na temperaturu u navedenom prvom rasponu.
Use of N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide polymorph B for the production of a medicament for the treatment of malignant tumors, auto - immune diseases, dermatological diseases and parasitism. 
Uporaba N-(2-aminofenil)-4-[N-(piridin-3-il)metoksikarbonilaminometiljbenzamid polimorfa B, naznačena time da se odnosi na proizvodnju lijeka za liječenje malignih tumora, autoimunih bolesti, kožnih bolesti i parazitizama.
The pharmaceutical composition according to [8], wherein the 5-FU antitumor agent is a combination drug comprising tegafur, gimeracil, and oteracil potassium. 
Farmaceutski sastav prema zahtjevu 5, naznačen time, da antitumorsko sredstvo 5-FU je kombinirani lijek koji sadrži tegafur, gimeracil i oteracil-kalij.
a coupling moiety which links the octadentate hydroxypyridinone-containing ligand to the targeting moiety, and 
vezujuću skupinu koja povezuje ligand koji sadrži oktadentat hidroksipiridinon na vezujuću skupinu, i
A process for preparing cortexolone-17a-propionate in cryslailine form III, wherein said crystalline form III is characterised by a DRX spectrum as represented in Figure 7 or 10 or 13 and by a DSC spectrum as represented in Figure 8 or 11 or 14 and by an IR spectrum as represented in Figure 9 or 12 or 15, said process comprising reacting a compound of formula II in an organic solvent with a compound of formula III R'OH (III) in the presence of a lipase from Candida, wherein R is CH3-CH2 and R' is a linear aliphatic chain containing 1 - 10 carbon atoms to give cortexolone-17 a-propionate, and crystallizing said cortexolone-17a-propionate from a mixture of dichloronzethane/n-hexane, or a mixture of acetone/n-hexane or a mixture of ethanol/water, to give cortexolone-17 a-propionate in crystalline form III. 
HR P20140421 T1 PATENTNI ZAHTJEVI Postupak dobivanja korteksolon-17a-propionata u kristalnom obliku III, gdje je navedeni kristalni oblik III naznačen time što ima DRX spektar, kao što je prikazan na Slici 7 ili 10 ili 13, što ima DSC spektar, kao što je prikazan na Slici 8 ili 11 ili 14, te što ima IR spektar, kao što je prikazan na Slici 9 ili 12 ili 15, gdje se navedeni postupak sastoji u reakciji spoja formule II o u organskom otapalu sa spojem formule III
Another clinically important aspect of this invention deals with a multicomponent microbicidal contraceptive intravaginal ringed-mesh device, described in the above paragraphs, is its adjunct use in preventing and treating tissue inflammation, herpes, cervical cancer, HIV and other retroviral, viral, and sexually transmitted diseases. 
Uređaj u vidu višekomponentne mikrobicidne kontraceptivne intravaginalne prstenaste mrežice u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen pomoćnoj upotrebi u sprječavanju i liječenju upale tkiva, herpesa, raka vrata maternice, HIV i drugih retrovirusnih, virusnih, te spolno prenosivih bolesti.
According to the preferred embodiment, the flat portion 60 has a first longitudinal side 62 and a second longitudinal side 63, the first and second longitudinal sides 62, 63 being connected by a combination of a straight front end portion 64 and a rounded front end portion 65, and the length of the first straight longitudinal side 62 of the base member 29 is somewhat shorter than the length of the second straight longitudinal side 63, which can be best seen in the top and bottom views of FIG. 
Zaklopka (20) prema patentnom zahtjevu 2, gdje ravan dio (60) ima prvu pravu uzdužnu stranu i drugu pravu uzdužnu stranu, pri čemu su prva i druga uzdužna strana povezane kombinacijom pravog prednjeg završnog dijela i zaobljenog prednjeg završnog dijela, gdje dužina prve uzdužne strane je kraća od dužine druge uzdužne strane.